Skip to main content
SpringerLink
Log in

Pharmacotherapy of Obesity

  • Chapter
Book cover The Management of Eating Disorders and Obesity

Part of the book series: Nutrition and Health ((NH))

  • 1698 Accesses

Abstract

Medicating for treatment of obesity can be a useful adjunct to diet and exercise and can help selected patients achieve and maintain meaningful weight loss. A report from the Heart, Lung and Blood Institute of the National Institutes of Health entitled Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report (1) emphasizes the need for physicians to address obesity in their patients. This report sanctions the clinical use of weight loss drugs approved by the US Food and Drug Administration (FDA) for long-term use as part of a concomitant lifestyle-modification program. Appropriate patients include those who have been unsuccessful in previous weight-loss attempts and whose BMI exceeds 27 kg/m2 who have associated conditions such as diabetes, hypertension, or dyslipidemia, or whose BMI exceeds 30 kg/m2. Still, for many physicians, treatment of obesity is not a routine part of their clinical practices, in part because of the stigma associated with medication usage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and treatment of overweight and obesity in adults—the Evidence report. Obes Res 1998; 6:51S–210S.

    Google Scholar 

  2. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20:805–875.

    Article  CAS  Google Scholar 

  3. Weintraub M, Bray GA. Drug treatment of obesity. Med Clin North Am 1989; 73:237–249.

    CAS  Google Scholar 

  4. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998; 18(3):231–236.

    Article  CAS  Google Scholar 

  5. Bray GA. Obesity—a time-bomb to be defused. Lancet 1998; 352:160–161.

    Article  CAS  Google Scholar 

  6. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581–588.

    Article  CAS  Google Scholar 

  7. Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999; 7:313–322.

    CAS  Google Scholar 

  8. Jick H. Heart valve disorders and appetite-suppressant drugs. JAMA 2000; 283:1738–1740.

    Article  CAS  Google Scholar 

  9. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999; 74:1191–1197.

    Article  CAS  Google Scholar 

  10. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134:261–266.

    CAS  Google Scholar 

  11. McMahon FG, Fujioka K, Singh, BN, et al. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension. Arch Int Med 2000; 160:2185–2191.

    Article  CAS  Google Scholar 

  12. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24:306–313.

    Article  CAS  Google Scholar 

  13. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8:399–402.

    CAS  Google Scholar 

  14. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1:352–354.

    CAS  Google Scholar 

  15. Greenway FL, Ryan Greenway FL, Ryan DH, et al. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7:523–531.

    CAS  Google Scholar 

  16. Astrup A, Breum L, Tourbro S, et al. The effect and satiety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes 1992; 16:260–277.

    Google Scholar 

  17. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7:477–484.

    CAS  Google Scholar 

  18. Foster GD, Wadden TA, Vogt RA, et al. What is a reasonable weight loss? Patients expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65:79–85.

    Article  CAS  Google Scholar 

  19. Bray GA. Evaluation of drugs for treating obesity. Obes Res 1995; 3:425S–434S.

    CAS  Google Scholar 

  20. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425–432.

    Article  CAS  Google Scholar 

  21. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000; 404:672–677.

    CAS  Google Scholar 

  22. National on the Task Force Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276:1907–1915.

    Article  Google Scholar 

  23. Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998; 22:S30–S42.

    Article  CAS  Google Scholar 

  24. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68:1180–1186.

    CAS  Google Scholar 

  25. Sykas SL, Danforth E Jr, Lien EL. Anorectic drugs which stimulate thermogenesis. Life Sci 1983; 33:1269–1275.

    Article  Google Scholar 

  26. Lupien JR, Bray GB. Effect of mazindol, D-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Pharmacol Biochem Behav 1986; 25:733–738.

    Article  CAS  Google Scholar 

  27. Scoville B. Review of amphetamine-like drugs by the Food and Drug Administration: Clinical data and value judgments. In: Obesity in Perspective. Pub. No. 75-708. Department of Health, Education, and Welfare, Washington, DC, 1975, pp. 441–443.

    Google Scholar 

  28. Silverstone JJ, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965; 19:395–398.

    CAS  Google Scholar 

  29. McKay RHG. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973; 1:489–493.

    CAS  Google Scholar 

  30. Langlois KJ, Forbes JA, Bell GW, Grant GF Jr. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res 1974; 16:289–296.

    CAS  Google Scholar 

  31. Gershberg H, Kane R, Hulse M, Pensgen E. Effects of diet and an anorectic drug (phentermine resin) in obese diabetics. Curr Ther Res 1977; 22:814–820.

    Google Scholar 

  32. Campbell CJ, Bhalla IP, Steel JM, Duncan LJP. A controlled trial of phentermine in obese diabetic patients. Practitioner 1977; 218:851–855.

    CAS  Google Scholar 

  33. Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981; 225:231–232.

    Google Scholar 

  34. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346:591–602

    Article  CAS  Google Scholar 

  35. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4:263–270.

    CAS  Google Scholar 

  36. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7:189–198.

    CAS  Google Scholar 

  37. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106:179–184.

    Article  CAS  Google Scholar 

  38. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000; 24:144–150.

    Article  CAS  Google Scholar 

  39. James WPT, Astrup A, Finer N, et al., for the STORM study group. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356:2119–2125.

    Article  CAS  Google Scholar 

  40. Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8:71–82.

    CAS  Google Scholar 

  41. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505–512.

    CAS  Google Scholar 

  42. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001; 142:489–497.

    Article  CAS  Google Scholar 

  43. Wirth A, Krause J. Long-term weight loss with sibutramine. JAMA 2001; 286:1331–1339.

    Article  CAS  Google Scholar 

  44. Fujioka K, Seaton TB, Rowe E, et al., and the Sibutramine/Diabetes clinical study group. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese type 2 diabetes mellitus. Diab Obes Metab 2000; 2:1–13.

    Article  Google Scholar 

  45. Gockel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24:1957–1960.

    Article  Google Scholar 

  46. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19:119–124.

    Article  CAS  Google Scholar 

  47. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16:5–11.

    Article  CAS  Google Scholar 

  48. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: A dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330–337.

    Article  CAS  Google Scholar 

  49. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind placebo-controlled study. Diab Obes Metab 2000; 2:105–112.

    Article  CAS  Google Scholar 

  50. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiol 2000; 94:152–158

    Article  CAS  Google Scholar 

  51. Sramek, JJ, Seiowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. Am J Hyperten 2002; 16:13–19.

    CAS  Google Scholar 

  52. Berube-Parent S, Prud’homme D, St-Pierre S, Doucet E, Tremblay A. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes Relat Metab Disord 2001; 25:1144–1153.

    Article  CAS  Google Scholar 

  53. Wadden RA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg CM. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001; 161:218–227.

    Article  CAS  Google Scholar 

  54. Van Gaal LF, Wauters M, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 1997; 21(Suppl 1): S5–S9.

    Google Scholar 

  55. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826–1832.

    Article  CAS  Google Scholar 

  56. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O’Neil PM. Bupropion SR significantly enhances weight loss: a 24-week double-blind, placebo-controlled trial with placebo group randomized to bupropion SR during 24-week extension. Obes Res 2002; 10:633–641.

    CAS  Google Scholar 

  57. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26:262–273.

    Article  CAS  Google Scholar 

  58. Reife R, Pledger G, Wu S. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41:S66–S71.

    Article  CAS  Google Scholar 

  59. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722–733.

    CAS  Google Scholar 

  60. DiMarzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410:822–825.

    Article  CAS  Google Scholar 

  61. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289:1820–1825.

    Article  CAS  Google Scholar 

  62. Montague CT Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903–908.

    Article  CAS  Google Scholar 

  63. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341:879–884.

    Article  CAS  Google Scholar 

  64. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568–1575.

    Article  CAS  Google Scholar 

  65. Huckshorn CJ, Saris, WH, Westerterp-Plantenga MS, et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85:4003–4009.

    Article  Google Scholar 

  66. Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Nat Acad Sci 2001; 98:4652–4657.

    Article  CAS  Google Scholar 

  67. Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289:1826–1832.

    Article  CAS  Google Scholar 

  68. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001; 107:379–386.

    CAS  Google Scholar 

  69. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101:515–520.

    CAS  Google Scholar 

  70. Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000; 8:317–323.

    CAS  Google Scholar 

  71. Hauptman J. Orlistat: selective inhibition of caloric absorption can affect long-term body weight. Endocrine 2000; 13:201–206.

    Article  CAS  Google Scholar 

  72. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997; 21(Suppl 3):S24–S30.

    CAS  Google Scholar 

  73. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharm 1998; 54:125–132.

    Article  Google Scholar 

  74. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352:167–172.

    Google Scholar 

  75. Davidson MH, Hauptman J, DiGirolamo M, et al. Long-term weight control and risk factor reduction in obese subjects treated with orlistat, a lipase inhibitor. JAMA 1999; 281:235–242.

    Article  CAS  Google Scholar 

  76. Hill JO, Hauptmann J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69:1108–1116.

    CAS  Google Scholar 

  77. Hauptmann J, Lucas C, Boldrin MN, Collins H, Segal KR for the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9:160–167.

    Article  Google Scholar 

  78. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G, on behalf of the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8:49–61.

    Article  CAS  Google Scholar 

  79. Lindgarde F, on behalf of the Orlistat Swedish Multimorbidity study group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity study. J Intern Med 2000; 248:245–254.

    Article  CAS  Google Scholar 

  80. Hollander P, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diab Care 1998; 21:1288–1294.

    Article  CAS  Google Scholar 

  81. Kelley D, Bray G, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes mellitus: a one-year, randomized, controlled trial. Diab Care 2002; 25:1033–1041.

    Article  CAS  Google Scholar 

  82. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diab Care 2002;25:1123–1128.

    Article  CAS  Google Scholar 

  83. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. JHypertens 1998; 16:2013–2017.

    Article  CAS  Google Scholar 

  84. Muls E, Kolanowski J, Scheen A, Van Gaal LF. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicenter study. Int J Obes Relat Metab Disord 2001; 25:1713–1721.

    Article  CAS  Google Scholar 

  85. Tonstad S, Pometta D, Erkelens DW, et al. The effects of gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46:405–410.

    Article  CAS  Google Scholar 

  86. Linton MF, Fazio S. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr Atheroscler Rep 2000; 2:29–35.

    Article  CAS  Google Scholar 

  87. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circ 2000; 101:207–213.

    CAS  Google Scholar 

  88. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321–1326.

    Article  CAS  Google Scholar 

  89. Tan MH. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl 2000; 113:54–62.

    CAS  Google Scholar 

  90. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metabol Res Rev 2000; 16:125–132.

    Article  CAS  Google Scholar 

  91. Sjostrom L et al. Xendos. Presentation. International Congress on Obesity, Sao Paolo, Brazil, 2002.

    Google Scholar 

  92. Reaven G, Segal K, Hauptman J, Boldrin M and Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with Syndrome X. Am J Cardiol 2001; 87:827–831.

    Article  CAS  Google Scholar 

  93. Drent ML, van der Veen EA. First clinical studies with orlistat: A short review. Obes Res 1995; 3:S623–S625.

    Google Scholar 

  94. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8:431–437.

    CAS  Google Scholar 

  95. Bray GA. Drug treatment of obesity. Endocr Metab Disor 2001; 2:403–418.

    Article  CAS  Google Scholar 

  96. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol 1985; 248:E507–E515.

    CAS  Google Scholar 

  97. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995; 3:537S–540S.

    CAS  Google Scholar 

  98. Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. Int J Obes Relat Metab Disord 1992; 16:715.

    CAS  Google Scholar 

  99. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003. Electronic publication in advance of print publication.

    Google Scholar 

  100. Larsen TM, Toubro S, van Baak MA, et al. No thermogenic effect after 28 days treatment with L-796,568, a novel β-3-adrenoceptor, in obese men. Obes Res 2000; 8(Suppl 1):44S.

    Google Scholar 

  101. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280:1596–600.

    Article  CAS  Google Scholar 

  102. Guerciolini R, Radu-Radulescu L, Boldrin M, Moore R. Fecal fat excretion induced by treatment with orlistat or chitosan: a 3-week randomized crossover design study. Obes Res 2000; 8:43S.

    Google Scholar 

  103. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999; 53:379–381.

    Article  CAS  Google Scholar 

  104. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001; 25:316–324.

    Article  CAS  Google Scholar 

  105. Boozer CN, Daly PA, Blanchard D, Nasser JA, Solomon JL, Homel P. Herbal ephedra/caffeine for weight loss: A 6-month safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26:593–604.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA

    George A. Bray MD

Authors
  1. George A. Bray MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicology, Indiana University School of Medicine and PRN Consulting, Indianapolis, IN

    David J. Goldstein MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc.,Totowa,NJ

About this chapter

Cite this chapter

Bray, G.A. (2005). Pharmacotherapy of Obesity. In: Goldstein, D.J. (eds) The Management of Eating Disorders and Obesity. Nutrition and Health. Humana Press. https://doi.org/10.1385/1-59259-865-X:241

Download citation

  • DOI: https://doi.org/10.1385/1-59259-865-X:241

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-341-1

  • Online ISBN: 978-1-59259-865-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation